Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes
Regular monitoring and open communication with healthcare providers ensure early identification and management of potential adverse effects
Results from these studies, expected in the coming years, will provide critical evidence regarding the potential neuroprotective effects of GLP-1 therapy
The brand's "Advanced nano-delivery matrix" claim addresses this directly - it implies a delivery system engineered to move botanical actives through the skin
This has led some researchers to speculate that reversion of brain network structure and activity to normal may underlie the therapeutic benefits of psychostimulant drugs
Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like peptide-1 (GLP-1), which is secreted in the gut when you eat and leads to reduced feelings of hunger